Saracatinib (AZD0530)

For research use only. Not for use in humans.

目录号：S1006 中文名称：塞卡替尼

Saracatinib (AZD0530) Chemical Structure

CAS No. 379231-04-6

Saracatinib (AZD0530)是一种有效的Src抑制剂，无细胞试验中IC50为2.7 nM，对c-Yes， Fyn， Lyn， Blk， Fgr和Lck也具有活性；但对Abl和EGFR (L858R和L861Q)活性较低。Saracatinib可诱导自噬。Phase 2/3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 746.35	现货
10mg	RMB 569.55	现货
200mg	RMB 5472.84	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Saracatinib (AZD0530)发表文献225篇：

Science, 2019, 365(6454)

PubMed: 31320558 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(1):35-49

PubMed: 29249464 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):807-822

PubMed: 30423298 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Int J Cancer, 2021, 10.1002/ijc.33606

PubMed: 33890294 ( click the link to review the publication )

Oncogene, 2021, 40(14):2567-2580

PubMed: 33686238 ( click the link to review the publication )

FASEB J, 2021, 35(5):e21598

PubMed: 33871068 ( click the link to review the publication )

J Mol Cell Cardiol, 2021, S0022-2828(21)00134-6

PubMed: 34216608 ( click the link to review the publication )

Neurobiol Dis, 2021, 156:105410

PubMed: 34087381 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):25

PubMed: 33677467 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 208:111693

PubMed: 33396024 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Arch Virol, 2021, 166(5):1433-1438

PubMed: 33683474 ( click the link to review the publication )

Life Sci Alliance, 2021, 4(4)e202000832

PubMed: 33574034 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107796

PubMed: 32579923 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):4235-4249e6

PubMed: 32209481 ( click the link to review the publication )

Cell Rep, 2020, 33(7):108398

PubMed: 33207193 ( click the link to review the publication )

Sci Signal, 2020, 13(650)eaba5754

PubMed: 32963013 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):148

PubMed: 32746865 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

J Neurosci, 2020, 40(34):6522-6535

PubMed: 32690613 ( click the link to review the publication )
Cell Death Dis, 2020, 12;11(2):118

PubMed: 32051399 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

PLoS Genet, 2020, 16(3):e1008694

PubMed: 32196488 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):311-320

PubMed: 31832986 ( click the link to review the publication )

J Immunol, 2020, 205(7):1953-1961

PubMed: 32848033 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0186.2020

PubMed: 33004621 ( click the link to review the publication )

Front Oncol, 2020, 3;10:442

PubMed: 32346533 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9276

PubMed: 33291786 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Sci Rep, 2020, 9;10(1):4355

PubMed: 32152351 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2020, 10.1152/ajplung.00444.2019

PubMed: 33325804 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.012957

PubMed: 32934005 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015489

PubMed: 33037073 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2020, 10.1152/ajpcell.00290.2020

PubMed: 32966125 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12982

PubMed: 32737414 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:2139-2151

PubMed: 32210580 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):31

PubMed: 31931755 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0224952

PubMed: 32692785 ( click the link to review the publication )

Neoplasia, 2020, 22(3):129-141

PubMed: 31981897 ( click the link to review the publication )

J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )
Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):296

PubMed: 30655532 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4349

PubMed: 31554791 ( click the link to review the publication )

J Exp Med, 2019, 216(4):807-830

PubMed: 30819724 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(5):1639-1649

PubMed: 30504425 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):3060-3076

PubMed: 31308216 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Cell Rep, 2019, 29(5):1311-1322.e5

PubMed: 31665642 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):132

PubMed: 31805962 ( click the link to review the publication )

Mol Metab, 2019, 28:36-47

PubMed: 31327757 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0608-1

PubMed: 31649319 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2135-2145

PubMed: 31484705 ( click the link to review the publication )

J Immunol, 2019, 203(11):2990-2999

PubMed: 31619538 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2019, 316(3):C377-C392

PubMed: 30566391 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Dev Comp Immunol, 2019, 96:1-8

PubMed: 30822451 ( click the link to review the publication )

Oncol Rep, 2019, 41(3):1911-1917

PubMed: 30628679 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3625-3632

PubMed: 31485668 ( click the link to review the publication )
Life Sci Alliance, 2019, 2(4)e201900425

PubMed: 31331982 ( click the link to review the publication )

Commun Biol, 2019, 2:156

PubMed: 31098401 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

Cancer Res, 2019, 79(19):5074-5087

PubMed: 31416844 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2068

PubMed: 29802342 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4259

PubMed: 30323235 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cancer Res, 2018, 78(4):985-1002.

PubMed: 29279356 ( click the link to review the publication )

Cancer Res, 2018, 78(22):6497-6508

PubMed: 30262461 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(21):2817-2836

PubMed: 29511352 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(23):3166-3182

PubMed: 29545604 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):887

PubMed: 30166523 ( click the link to review the publication )

FASEB J, 2018, 32(6):3033-3046

PubMed: 29401603 ( click the link to review the publication )

Neurobiol Dis, 2018, 110:102-121

PubMed: 29197620 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Metallomics, 2018, 10(8):1141-1159

PubMed: 30066004 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Exp Cell Res, 2018, 364(2):208-216

PubMed: 29427623 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )
Cancer Med, 2018, 7(2):408-419

PubMed: 29318780 ( click the link to review the publication )

Cancer Med, 2018, 7(3):820-830

PubMed: 29383859 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):447-454

PubMed: 29749519 ( click the link to review the publication )

Viruses, 2018, 10(6)

PubMed: 29795047 ( click the link to review the publication )

Tumour Biol, 2018, 40(8):1010428318794217

PubMed: 30124118 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(2):106-119

PubMed: 28114269 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

J Clin Invest, 2017, 127(4):1338-1352

PubMed: 28240606 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

J Natl Cancer Inst, 2017, 1;109(9):djx014

PubMed: 28376152 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

J Exp Med, 2017, 214(9):2715-2732

PubMed: 28838952 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):1643-1648

PubMed: 28130546 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3571-3590

PubMed: 28972102 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cell Rep, 2017, 20(12):2775-2783

PubMed: 28930674 ( click the link to review the publication )

Cell Rep, 2017, 20(4):999-1015

PubMed: 28746882 ( click the link to review the publication )

Cell Rep, 2017, 21(2):533-545

PubMed: 29020637 ( click the link to review the publication )
Cell Rep, 2017, 18(3):804-815

PubMed: 28099856 ( click the link to review the publication )

Sci Signal, 2017, 10(460)

PubMed: 28049762 ( click the link to review the publication )

J Med Chem, 2017, 60(18):7863-7875

PubMed: 28792760 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

J Virol, 2017, 91(21)

PubMed: 28814523 ( click the link to review the publication )

PLoS Comput Biol, 2017, 13(3):e1005432

PubMed: 28306714 ( click the link to review the publication )

J Cancer, 2017, 8(11):1943-1951

PubMed: 28819393 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Leuk Res, 2017, 61:44-52

PubMed: 28888102 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):494-506

PubMed: 28346091 ( click the link to review the publication )

Cancer Genet, 2017, 216-217:128-141

PubMed: 29025587 ( click the link to review the publication )

Biotechnol J, 2017, 12(10)

PubMed: 28786556 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103014-103031

PubMed: 29262541 ( click the link to review the publication )

Oncotarget, 2017, 8(48):83872-83889

PubMed: 29137389 ( click the link to review the publication )

Oncotarget, 2017, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Oncotarget, 2017, 8(61-:103014-103031

PubMed: 29262541 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Sci Transl Med, 2016, 8(354):354ra114

PubMed: 27582059 ( click the link to review the publication )

Theranostics, 2016, 6(4):594-609

PubMed: 26941850 ( click the link to review the publication )

Cancer Res, 2016,

PubMed: 27216177 ( click the link to review the publication )
Sci Signal, 2016, 9(448):ra97

PubMed: 27703030 ( click the link to review the publication )

Brain Behav Immun, 2016, 55:236-248

PubMed: 26721416 ( click the link to review the publication )

Cell Death Dis, 2016, 7(12):e2572

PubMed: 28032865 ( click the link to review the publication )

PLoS Genet, 2016, 12(3):e1005931

PubMed: 26978032 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(9):2198-208

PubMed: 27256378 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(2):509-21

PubMed: 27186420 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(10):1555-68

PubMed: 26976639 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

Toxicology, 2016, 370:94-105

PubMed: 27693619 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(3):563-570

PubMed: 27666484 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27285768 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Sci Signal, 2015, 8(400):ra106

PubMed: 26508788 ( click the link to review the publication )

Stem Cells, 2015, 10.1002/stem.1990

PubMed: 25788415 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2238-48

PubMed: 26208525 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):377-88

PubMed: 25306394 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(15):4296-305

PubMed: 25948553 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(12):2687-96

PubMed: 26390252 ( click the link to review the publication )

FEBS J, 2015, 10.1111/febs.13314

PubMed: 25940608 ( click the link to review the publication )
Biochem J, 2015, 468(3):495-506

PubMed: 25846210 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Pancreas, 2015, 44(1):152-7

PubMed: 25222135 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142219

PubMed: 26556238 ( click the link to review the publication )

Mol Cell Biochem, 2015, 407(1-2):197-207

PubMed: 26045172 ( click the link to review the publication )

J Biomol Screen, 2015, 20(10):1286-93

PubMed: 26384394 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Nature, 2015, 519(7541):57-62

PubMed: 25731159 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22098-113

PubMed: 26061747 ( click the link to review the publication )

Oncotarget, 2015, 6(30):29991-30005

PubMed: 26358373 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9476-87

PubMed: 25823815 ( click the link to review the publication )

Neurotherapeutics, 2015, 12(1):132-42

PubMed: 25549849 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25897-916

PubMed: 26317790 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(5):401-14

PubMed: 24705551 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3003-15

PubMed: 24911146 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4762-71

PubMed: 25023728 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(3):R45

PubMed: 24887236 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-38

PubMed: 24482380 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )
J Chem Inf Model, 2014, 54(3):881-93

PubMed: 24490903 ( click the link to review the publication )

Ultrasound Med Biol, 2014, 40(6):1177-86

PubMed: 24612644 ( click the link to review the publication )

Placenta, 2014, 35(10):824-30

PubMed: 25108485 ( click the link to review the publication )

Oncotarget, 2014, 6(3)

PubMed: 25596741 ( click the link to review the publication )

University of Manche, 2014, aus Landshut

PubMed: ( click the link to review the publication )

J Neurooncol, 2014, 120(1):33-41

PubMed: 25048528 ( click the link to review the publication )

Oncotarget, 2014, 5(19):8853-68

PubMed: 25326682 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Pac Symp Biocomput, 2014, 2014:125-35

PubMed: 24297540 ( click the link to review the publication )

Dissertation zur Erlangung des Doktorgrades, 2014,

PubMed: ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Cell Biol, 2013, 15(4):395-405

PubMed: 23455479 ( click the link to review the publication )

Blood, 2013, 122(7):1203-13

PubMed: 23836556 ( click the link to review the publication )

J Clin Invest, 2013, 123(5):2037-48

PubMed: 23543053 ( click the link to review the publication )

Int J Cancer, 2013, 132(1):224-35

PubMed: 22623106 ( click the link to review the publication )

Breast Cancer Res, 2013,

PubMed: 24044505 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e915

PubMed: 24201814 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

Biochimica et Biophysica Acta, 2013, 1829(10):1147-59

PubMed: 23948603 ( click the link to review the publication )

Mol Carcinog, 2013, 10.1002/mc.22092

PubMed: 24127286 ( click the link to review the publication )

PLoS One, 2013, 8(4):e60889

PubMed: 23593342 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )
Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(6):379-88

PubMed: 22313687 ( click the link to review the publication )

Cancer Res, 2011, 71(24):7547-57

PubMed: 21994334 ( click the link to review the publication )

Mol Cancer Res, 2011, 9(3):249-58

PubMed: 21296861 ( click the link to review the publication )

Mol Endocrinol, 2011, 25(12):2041-53

PubMed: 22053001 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

Transl Oncol, 2011, 4(2):92-100

PubMed: 21461172 ( click the link to review the publication )

Methods Mol Biol, 2011, 685:91-109

PubMed: 20981520 ( click the link to review the publication )

Mol Endocrinol, 2010, 24(6):1151-64

PubMed: 20371703 ( click the link to review the publication )

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述

特性

Saracatinib是第一个作用于人类肿瘤组织Src通路的抑制剂。

靶点

c-Src ^[2] (Cell-free assay)	LCK ^[2] (Cell-free assay)	c-YES ^[2] (Cell-free assay)	EGFR (L861Q) ^[2] (Cell-free assay)	Lyn ^[2] (Cell-free assay)	点击更多
2.7 nM	<4 nM	4 nM	4 nM	5 nM	点击更多

体外研究

Saracatinib也有效抑制其他Src酪氨酸激酶家族成员，包括c-Yes, Fyn, Lyn, Blk, Fgr, 和Lck，IC50为4到10 nM。Saracatinib有效抑制SrcY530F突变的NIH 3T3细胞，IC50为80 nM。在NBT-II膀胱癌细胞中，Saracatinib显著阻断HT1080细胞通过立体骨胶原基质的入侵，且完全抑制EGF诱导的细胞分散。^[1]Saracatinib作用于DU145和PC3细胞，通过抑制Y419磷酸化而有效抑制Src激活。Saracatinib抑制前列腺癌包括PC3, DU145, CWR22Rv1和 LNCaP的生长，而Saracatinib作用于 LAPC-4, PZ-HPV7和RWPE-1细胞时却显示低活性。Saracatinib使细胞周期停止在G1/S期，但是不使caspase 3断裂。Saracatinib 也明显抑制Boyden 小室的DU145和PC3 移动。^[2]Saracatinib有效且持久抑制Akt，且增强A549和Calu-6细胞对放射处理的敏感性。^[3]Saracatinib在活性，再吸收，及组成上抑制蚀骨细胞。Saracatinib也可逆阻断蚀骨细胞前体的移动。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
CTV-1	Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV7JR\|UxRTBwME[xOFMh\|ryP	M2rtcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LAMA-84	NVrXd4twT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUnJ[\|RsUUN3ME2wMlE2QTlizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
MEG-01	M37LUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVTJR\|UxRTBwMkO2PFgh\|ryP	Mof0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
EM-2	M3W3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NG\5TmZKSzVyPUCuNlY2KM7:TR?=	M3\JbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
TE-15	MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYrJR\|UxRTBwMke0NVIh\|ryP	M32wSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NCI-H1648	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVrxeJNQUUN3ME2wMlI5OTF4IN88US=>	MnOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TE-12	NVfZdXpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlrmTWM2OD1yLkOyOlgh\|ryP	NF\Pd449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
LB996-RCC	NWexcGp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUHJR\|UxRTBwNESxPVYh\|ryP	NIfUW5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
K-562	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWDKb5ROUUN3ME2wMlQ1QTZ5IN88US=>	M1HlW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
D-336MG	NHfjVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUXJR\|UxRTBwNUCzNFQh\|ryP	NVqzTlUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NOS-1	M3GwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYHJR\|UxRTBwNkC1Nlkh\|ryP	M1rvXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
EW-24	M3ezeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnTPTWM2OD1yLk[yOlk{KM7:TR?=	M3rLdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
BV-173	NUW4Omp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1PqTGlEPTB;MD62OVI1QSEQvF2=	NV7RUIN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NCCIT	NXTsV2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX3KTXR4UUN3ME2wMlc{OjF6IN88US=>	M4XkeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NCI-H1436	NH;sPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYPneYliUUN3ME2wMlc6ODR7IN88US=>	NEnLU2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
BB30-HNC	M1T2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF7tcY1KSzVyPUCuPFYzODNizszN	MomyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TE-8	M3HjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYfJR\|UxRTBwOEeyO\|Uh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
A704	M2HlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3m4dGlEPTB;MD64PVIyKM7:TR?=	NILOc4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TK10	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml7yTWM2OD1yLkmwOlY6KM7:TR?=	NY\PWWxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KS-1	NVfwe\|YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFzCfJRKSzVyPUGuNVk4PzlizszN	MlnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
C2BBe1	NWPSXHNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGLveWhKSzVyPUGuNlA2ODdizszN	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
RXF393	M37GcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mnz2TWM2OD1zLkK0N\|Yh\|ryP	MkfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KGN	NGfjRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkjnTWM2OD1zLkK3Olg4KM7:TR?=	MnP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NB69	NGjZcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGC0U2dKSzVyPUGuN\|c1QTdizszN	M4XWT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
TE-11	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEjRcWhKSzVyPUGuOFM1OThizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TE-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3zuU2lEPTB;MT60OFExPSEQvF2=	NHjWT4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
ST486	NH25ZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3XjXGlEPTB;MT60OVg2OiEQvF2=	M{LYRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
HOP-62	NVP2do9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{\MWmlEPTB;MT61NFI1PiEQvF2=	MmHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
EW-16	M1zVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXHJR\|UxRTFwNUWwPFMh\|ryP	Mm\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	M3rJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWn4SWV6UUN3ME2xMlU2PDV\|IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
TE-10	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mm\QTWM2OD1zLk[2NlUzKM7:TR?=	M4LzcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
RL95-2	NUG4PZQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHrUcmpKSzVyPUGuOlY6ODJizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
DOHH-2	MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml:xTWM2OD1zLkexO\|gzKM7:TR?=	MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
MFH-ino	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUfaNo9nUUN3ME2xMlc4QDdizszN	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
GB-1	NFvXZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1fLXmlEPTB;MT63PVg{OyEQvF2=	MlPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SK-N-DZ	NVLINZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYXtenRmUUN3ME2xMlg1Pjh6IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
OS-RC-2	NHfNZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWLhO2tQUUN3ME2xMlg5PTd2IN88US=>	MoTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SW982	NYTid2VPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX7JR\|UxRTFwOUKwPVMh\|ryP	M3TvOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
KALS-1	MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{DEemlEPTB;MT65PFczOiEQvF2=	NWXncnl5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
TGBC24TKB	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mo\LTWM2OD1{LkC1PVU5KM7:TR?=	MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
GI-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYPFeodLUUN3ME2yMlE3ODh2IN88US=>	M3rqS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SW962	NI\VTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4\LcWlEPTB;Mj6xO\|E4QCEQvF2=	M{LSW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SW872	NFf5e\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFvWVHZKSzVyPUKuNVg2ODdizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H747	NVjmZ3l[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkTWTWM2OD1{LkK1O\|E1KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
MZ1-PC	NX3teZExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4LBcWlEPTB;Mj6yPVM2PiEQvF2=	NGr3WmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
MSTO-211H	M132TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1jFOmlEPTB;Mj6zOVczOyEQvF2=	M1vTXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
BL-70	NWDnfHdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVfJR\|UxRTJwNEe0NlIh\|ryP	M4WySVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SW954	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4LZOmlEPTB;Mj61O\|QxQCEQvF2=	NXPydZpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SNB75	NIXlVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1;Nc2lEPTB;Mj62PFU6PCEQvF2=	M4XnWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
IST-SL2	NGG3R4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mk\rTWM2OD1{LkeyN\|c6KM7:TR?=	NVPXT3Y4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GCIY	NXWwdplvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIHr[Y5KSzVyPUKuPFcxODVizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KU812	Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYLKc\|M6UUN3ME2zMlA2Ojl7IN88US=>	M1nLXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LXF-289	NG\KfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUG0W5NRUUN3ME2zMlEzOTB7IN88US=>	NFPUSHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
ETK-1	M2HB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mk\RTWM2OD1\|LkKwO\|Y4KM7:TR?=	NGTVWVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SF126	NGPESW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4Ht[2lEPTB;Mz6zNVE4PCEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
LC-2-ad	NVfkNnhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVfJR\|UxRTNwNUW3JO69VQ>?	MmXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KNS-42	NGTYd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlXLTWM2OD1\|Lk[1JO69VQ>?	NXPSUJh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
OVCAR-4	NYDlRVVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1G1W2lEPTB;Mz63N\|Q{OyEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
PF-382	M2fPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmTFTWM2OD1\|LkizOlk5KM7:TR?=	NWD6b21vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SH-4	NV3R[I1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYHEWnR4UUN3ME20MlI2OjV7IN88US=>	M2TPR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
KM12	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnTZTWM2OD12LkOyOFE3KM7:TR?=	M4TMU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NB5	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGnQRZJKSzVyPUSuOFE5PjRizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KURAMOCHI	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoTZTWM2OD12Lk[1NlU3KM7:TR?=	NXfifFlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
Becker	Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1WweWlEPTB;ND62OlQyPiEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
MV-4-11	NFfWWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml:xTWM2OD12LkixN\|Q1KM7:TR?=	MmG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KINGS-1	NH;KS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1;hZ2lEPTB;ND64NlM4OyEQvF2=	M{HGTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LS-123	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUXJR\|UxRTVwNEm2PFQh\|ryP	NVXvTmd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
SF268	M{KxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M13TfmlEPTB;NT62NVI3OiEQvF2=	M3;lUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
A388	NXPJWFdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3rFfGlEPTB;NT62N\|Y3PyEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NMC-G1	NV3o[3RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGX6botKSzVyPU[uNFE5OTFizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
CGTH-W-1	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHvpNoJKSzVyPU[uNFIxPzVizszN	NIm4XYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
ES4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NULUTok4UUN3ME22MlU{ODd2IN88US=>	M2XHfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SR	NHLTe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmqyTWM2OD14LkW4PFA4KM7:TR?=	NFvHSIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
BB49-HNC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUTJR\|UxRTZwN{OyNFYh\|ryP	NVr1Zmx5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
KLE	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NITKcJhKSzVyPU[uO\|g{PzdizszN	MkOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
HUTU-80	M2DPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MljQTWM2OD14Lkm4OFY3KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SNU-C2B	NYHYVGFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIi3XZZKSzVyPUeuPFI4OzdizszN	NWH3eJg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
BB65-RCC	M{\kUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2GwbWlEPTB;Nz65OFkxPCEQvF2=	MoPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmTlTWM2OD16LkSyPFA5KM7:TR?=	MoH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
GDM-1	NEHVdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MorXTWM2OD16Lkm3NlkzKM7:TR?=	NX:1OlRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LC4-1	NEnneWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYrLc5B2UUN3ME25MlAxQTFzIN88US=>	NXHpZW46RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
MLMA	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXnJR\|UxRTlwMUWwNFYh\|ryP	M1v5cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
EoL-1-cell	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1[4TmlEPTB;OT6zNFE6OiEQvF2=	NF;WUpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
BOKU	M2PCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXfJR\|UxRTlwOU[0OlYh\|ryP	NXXseo8{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
EVSA-T	NF\sUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFi1V\|JKSzVyPUGwMlY2PjhizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
D-283MED	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{PLN2lEPTB;MUCuPVE4PiEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB1	M2nWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVnJR\|UxRTFzLkCyOFIh\|ryP	NVXQ[Y5uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
RPMI-8402	M4TOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3LXSWlEPTB;MUGuNVc5KM7:TR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NCI-H1355	NV\ZVY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXLkS3VPUUN3ME2xNU4yQDB4IN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
NB7	MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHm5SIVKSzVyPUGxMlMzQTdizszN	MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
RPMI-6666	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHXtR\|lKSzVyPUGyMlk2PjdizszN	MmXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
697	M17rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3XlR2lEPTB;MUOuNlcxOSEQvF2=	MmraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
CTB-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnvFTWM2OD1zMz61PVQ5KM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
VA-ES-BJ	NHj0UWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWDXdmhzUUN3ME2xN{46OjN2IN88US=>	MoLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
BE-13	NIXwO\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVPJR\|UxRTF2LkO5NVUh\|ryP	Mn;YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SKM-1	M3zJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH;jUmdKSzVyPUG0MlQ1QTlizszN	NFLzRpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
TE-6	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlLOTWM2OD1zND63OVkyKM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
LB771-HNC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2rOUmlEPTB;MUSuO\|g6QCEQvF2=	MkS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
ECC4	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlO5TWM2OD1zNz6wNlc4KM7:TR?=	M4TvbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
ES3	NHL1[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXLJR\|UxRTF5LkS2OVUh\|ryP	NYPMO3o5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
LB647-SCLC	NFW0ZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUXPPZpnUUN3ME2xO{41QTR7IN88US=>	NF\6OGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
NB10	Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MljiTWM2OD1zOD61NlU3KM7:TR?=	MmjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
L-540	NEPN[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{HRcmlEPTB;MUiuPFExQSEQvF2=	MkW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NCI-H2126	M4T4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXfJR\|UxRTF7LkWxJO69VQ>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
HH	NGXQXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXXRcYVYUUN3ME2yNE4xODl7IN88US=>	NF7VUpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
MPP-89	Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NE\RUpNKSzVyPUKzMlIzQDlizszN	NG\TV2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
IST-MEL1	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MojiTWM2OD1{Mz64OlU5KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
KP-N-YS	NFPmOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2rtPGlEPTB;MkOuPVI2PSEQvF2=	M1jub\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
EC-GI-10	MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml7rTWM2OD1{ND61PVg6KM7:TR?=	M1H2SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
EKVX	NEDmU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUDJR\|UxRTJ4LkCyNFMh\|ryP	MkLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TGBC1TKB	NUXSeHprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX7Lc5pkUUN3ME2yOk41OzRizszN	NUfXcWR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
Daudi	MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn61TWM2OD1{Nz6wO\|c{KM7:TR?=	MoPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
ALL-PO	NIi4SWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkjOTWM2OD1{Nz6wPFEh\|ryP	NIO4dVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
NB6	M2XFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEDKfGhKSzVyPUK3MlQ5QCEQvF2=	NWH6S\|RjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
ES6	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH3HRYtKSzVyPUK3MlkyOjNizszN	NWXDUGJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
COLO-320-HSR	NHfjTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1TFOGlEPTB;MkiuNFM4OyEQvF2=	NYT0dJNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
K5	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3TNNWlEPTB;MkiuNVI5PyEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
ES1	MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NY\vWY1lUUN3ME2yPE44Pzd\|IN88US=>	M3nrZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
LC-1F	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWjJR\|UxRTJ7LkezOFYh\|ryP	Mnq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
SCLC-21H	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmW5TWM2OD1\|MD63N\|E4KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVcxQTJxJ{7TRW5ITVJ:L3G+
SK-PN-DW	NWjzZnNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV3TTYJ3UUN3ME2zNk42PTl6IN88US=>	NIjxU2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
D-247MG	NHf2bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnHxTWM2OD1\|Mj65O\|c{KM7:TR?=	Ml;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TE-5	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M161NmlEPTB;M{OuNFM3OiEQvF2=	NX:yNI4xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
MONO-MAC-6	NYC1b3ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2fsPWlEPTB;M{OuOVA1QCEQvF2=	Mmj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LB2518-MEL	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWn6U5BiUUN3ME2zN{44PjZ4IN88US=>	Mne3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
LOXIMVI	NGmzPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnfRTWM2OD1\|Mz63PVI5KM7:TR?=	MkHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
NCI-H209	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWrRZVlPUUN3ME2zOU4yPDRizszN	NGnGfG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
A253	Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFK5R2xKSzVyPUO1Mlc1OjlizszN	NY[1OJd1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
HCC1599	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVTGbmtpUUN3ME2zOk44ODV\|IN88US=>	NXvvNFZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
EB-3	NFTjVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmP5TWM2OD1\|Nj65OVE5KM7:TR?=	NYDyVZVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
GOTO	NFOzd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkfUTWM2OD1\|Nz6zNlI1KM7:TR?=	M3HvVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
SW684	NWLvUZk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWPQS4ZsUUN3ME20NU45PDl3IN88US=>	MmrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
DEL	NH\aPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVXJR\|UxRTR{LkC1NlIh\|ryP	M1jUVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
HT-144	Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFTnRnhKSzVyPUSyMlE3PzZizszN	Ml;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
TE-9	NIXTOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoTOTWM2OD12Mz60OVk3KM7:TR?=	MoC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KARPAS-45	M2\Jcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXvhe5NNUUN3ME20OE4{QTJ3IN88US=>	M4PmVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
HAL-01	Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1zVW2lEPTB;NESuOVA{PCEQvF2=	M37qfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
RCC10RGB	NULOTWhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3vFbWlEPTB;NESuO\|M6OiEQvF2=	NXTqO4dwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
CP67-MEL	M3jVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGr0UWZKSzVyPUS1MlYzPDFizszN	NXKycnFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
NB17	NXH3VZNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXr4UoZGUUN3ME20OU43PjR\|IN88US=>	NFjjXHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
SK-UT-1	M2O3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlPPTWM2OD12NT65OFY1KM7:TR?=	NUTyO482RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjF5MEmyM{c,W0GQR1XSQE9iRg>?
JiyoyeP-2003	M321PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3HBUWlEPTB;NE[uNFEyQSEQvF2=	MnHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
HCE-4	Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3LZZmlEPTB;NE[uOVk3QCEQvF2=	NHjQT2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
NCI-H720	Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmL6TWM2OD12Nj63OlgzKM7:TR?=	Ml:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlE4ODl{Lze+V2FPT0WUPD;hQi=>
KARPAS-422	Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3f5cGlEPTB;NEeuNFg6PSEQvF2=	M2HweVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	NVrNW\|JwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3LlTWlEPTB;NEeuNVYzOiEQvF2=	NEHiOm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTdyOUKvK\|5USU6JRWK8M4E,
HCE-T	M4KxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NG\XVINKSzVyPUS3MlY5OjhizszN	M1HhOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
PSN1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mmm3TWM2OD12Nz63PFE{KM7:TR?=	M3nudFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyPzB7Mj:nQnNCVkeHUkyvZV4>
NIH3T3	Ml;uSpVv[3Srb36gZZN{[Xl?			NEPnV2xKdmirYnn0bY9vKG:oIHj1cYFvKGNvU4LjJIlvKE6LSEPUN{Bk\WyuczygTWM2OCB;IECuNFAzPyEQvF2u	MmPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyNkSwOlYoRjF5ME[0NFY3RC:jPh?=
HEK293	MWPGeY5kfGmxbjDhd5NigQ>?		NGjEOJoyKGi{	MWTJcohq[mm2aX;uJI9nKGi3bXHuJIZ2dGxibHXu[5RpKFCNTWnUNUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJV{cW6pIFXGV{ApOjR5IITvJFI2QSC{ZYPp[JVmeyliYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCrbX31co9ie2G7LDDLbUA:KDBwMEO5PEDPxE1w	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl2MUG5N{c,Ojl7NEGxPVM9N2F-
HEK293	M{nSRWZ2dmO2aX;uJIF{e2G7		MnnLNUBpeg>?	Mm\qTY5pcWKrdHnvckBw\iCqdX3hckBnfWyuIHzlcod1cCCSS13ZWFEh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{B2e2mwZzDFSnMhMDJ2NzD0c{AzPTlicnXzbYR2\XNrIHHzJJN2[nO2cnH0[UBi\nSncjCxJIhzKGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iaX3teY5w[XOjeTygTWM2OCB;IECuOFE5KM7:TT6=	NGjQWpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NVE6Oyd-Mkm5OFEyQTN:L3G+
Rh30	MlTERY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M4XkSVQ5KGi{cx?=	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKqM{CgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[XO\|YYmsJGlEPTBiPTCxNE4yKM7:TT6=	M1XsdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{i3NFk6Lz5{M{e4O\|A6QTxxYU6=
Huh7	MkjnRY51cX[rcnHsJIF{e2G7	MUOyMlUhfU1?	NHHsOJk2KGSjeYO=	M1;BPGlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDoeY1idiCKdXi3JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVOKGGodHXyJFUh\GG7czDifUBqdW23bn;mcJVwemW\|Y3XuZ4Uh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
Huh7	NH\tdJNCdnSrdnnyZYwh[XO\|YYm=	M1zkUlIvPSC3TR?=	M374UFYh\GG7cx?=	NXXoR2w{UW6qaXLpeIlwdiCxZjD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1iYX\0[ZIhPiCmYYnzJIJ6KGmvbYXuc4ZtfW:{ZYPj[Y5k\SCjc4PhfUBz\WyjdHn2[UB1dyClb370do9t	NIH1W5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O2NFY4Pid-MUezOlA3PzZ:L3G+
Vero	NXPTWmZiSW62aY\pdoFtKGG\|c3H5	MoLxNk42KHWP	NYLnVXJUPCCmYYnz	MVHJcohq[mm2aX;uJI9nKH[rcnHsJJNxemWjZDDpckBF\W6pdXWgeolzfXNvaX7m[YN1\WRiYX\ybYNidiCpcnXlckBud26tZYmgWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TTDh[pRmeiB2IHThfZMh[nliaX3teY5w\my3b4Lld4NmdmOnIHHzd4F6KHKnbHH0bZZmKHSxIHPvcpRzd2x?	M{XrZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
Vero	MVfBcpRqfmm{YXygZZN{[Xl?	NYLsPGJ{Oi53IIXN	MXq2JIRigXN?	NFWx[mZKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgZYZzcWOjbjDndoVmdiCvb37r[ZkhXmW{bzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44hd2ZidnnyZYwh\W64ZXzvdIUheHKxdHXpckB4cXSqaX6gdIVzcW63Y3zlZZIhemWpaX;uJIF1KDJwNTD1UUBi\nSncjC2JIRigXNiYomgbY1ufW6xZnz1c5Jme2OnbnPlJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y=	MkXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC2O\|YoRjF5M{[wOlc3RC:jPh?=
C6/36	NYnr[5RGSW62aY\pdoFtKGG\|c3H5	MU[yMlUhfU1?	M{fLXlQh\GG7cx?=	NIjkR3pKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgZZNq[W5idHnn[ZIhdW:\|cYXpeI8hSzZxM{[gZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oII\pdoFtKGWwdnXsc5BmKHC{b4TlbY4hf2m2aHnuJJBmemmwdXPs[YFzKHKnZ3nvckBifCB{LkWgeW0h[W[2ZYKgOEBl[Xm\|IHL5JIludXWwb3\seY9z\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s	M{HSXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
C6/36	M1H2WmFvfGm4aYLhcEBie3OjeR?=	MknRNk42KHWP	NIPmVHo2KGSjeYO=	M4O0dWlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDhd4lidiC2aXfldkBud3OzdXn0c{BEPi9\|NjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44hd2ZidnnyZYwh\W64ZXzvdIUheHKxdHXpckB4cXSqaX6gdIVzcW63Y3zlZZIhemWpaX;uJIF1KDJwNTD1UUBi\nSncjC1JIRigXNiYomgbY1ufW6xZnz1c5Jme2OnbnPlJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4ME[3Okc,OTd\|NkC2O\|Y9N2F-
Vero	MlLjRY51cX[rcnHsJIF{e2G7		M2rzOVMh\GG7cx?=	Mlv0RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgSIVv\3WnII\pdpV{KGmwZnXjeIVlKGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JHZmem9iY3XscJMh[WSvaX7pd5RmemWmIHHmeIVzKH[rcnHsJINp[WyuZX7n[UBi\nSncjCzJIRigXNiYomgeolz[WxicHzhdZVmKGG\|c3H5	MmK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC2O\|YoRjF5M{[wOlc3RC:jPh?=
Vero	MnqyRY51cX[rcnHsJIF{e2G7	MYeyMlUhfU1?	MVG1JIRigXN?	M3LoXGlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXNJIFnfGW{IEWg[IF6eyCkeTDpcY12dm:obIXvdoV{[2WwY3WgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbB?=	NVfCcm9GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
Huh7	NVOxdGpSSW62aY\pdoFtKGG\|c3H5	NXPKdYdOOi53IIXN	M4fZWlQh\GG7cx?=	NHfsSnNKdmirYnn0bY9vKG:oII\pdoFtKHOycnXh[EBqdiCGZX7neYUhfmm{dYOtbY5n\WO2ZXSgbJVu[W5iSIXoO{Bk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VSCjZoTldkA1KGSjeYOgZpkhcW2vdX7v[ox2d3Knc3PlcoNmKGG\|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4w>	NVmyPFNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
C6/36	NVLENYhVSW62aY\pdoFtKGG\|c3H5	NHnZZm4zNjVidV2=	Mnn2OkBl[Xm\|	M3fXeWlvcGmkaYTpc44hd2ZidnnyZYwhe3C{ZXHkJIlvKESnbnf1[UB3cXK3cz3pcoZm[3SnZDDhd4lidiC2aXfldkBud3OzdXn0c{BEPi9\|NjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44hd2ZidnnyZYwh\W64ZXzvdIUheHKxdHXpckB4cXSqaX6gdIVzcW63Y3zlZZIhemWpaX;uJIF1KDJwNTD1UUBi\nSncjC2JIRigXNiYomgbY1ufW6xZnz1c5Jme2OnbnPlJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y=	NVrBS4dyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
HEK293	NXux[3JOTnWwY4Tpc44h[XO\|YYm=	NFj2do0xNjFidH:gNUB2VQ>?	NEThUpQyPiCqcoO=	NET1XW1KdmirYnn0bY9vKG:oIHPvcIxi\2WwIFmtbY5lfWOnZDDESHIzKCi3bnvuc5dvKG:{aXfpckkheGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZQhOC5zIITvJFEhfU1iYX\0[ZIhOTZiaILzJIJ6KFenc4Tldo4h[myxdITpcoc>	MmDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOUGzOlkoRjJ4MUmxN\|Y6RC:jPh?=
A673	NWXVR3FseUiWUzDhd5NigQ>?			NXS2foRmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	M1XYdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	MkfXdWhVWyCjc4PhfS=>			NEHVTlRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	NYfSS3cyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NGjwN2JyUFSVIHHzd4F6			M{THO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	NXvZOIVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	MnnodWhVWyCjc4PhfS=>			NUfHTZZReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NUnEfY9XeUiWUzDhd5NigQ>?			MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NF\TeXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	M3fLbJFJXFNiYYPzZZk>			NFXZbGFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	Ml\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MkTsdWhVWyCjc4PhfS=>			NH7ZR4hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MlfkdWhVWyCjc4PhfS=>			M2nrSJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	M{\WN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NVH5fWJQeUiWUzDhd5NigQ>?			NGDDbItyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	MlPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
HEK293	Ml\ZSpVv[3Srb36gZZN{[Xl?	NY\OT\|ZGOC5zIITvJFEhfU1?	Ml:zNVYhcHK\|	M1;YTWlvcGmkaYTpc44hd2ZiY3;scIFo\W5iST3pcoR2[2WmIFTEVlIhUTZ\|OF[gcZV1[W62IDj1cotvd3ewIH;ybYdqdilicHjvd5Bpd3K7bHH0bY9vKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XRiMD6xJJRwKDFidV2gZYZ1\XJiMU[gbJJ{KGK7IGfld5Rmem5iYnzveJRqdmd?	NYTvNoZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xPVE{PjlpPkK2NVkyOzZ7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pY576-FAK / pY861-FAK / FAK; PubMed: 20551056 Cancer Res (A) HCT116 (left) and WiDr (right) cells were exposed to the indicated concentrations of saracatinib for 24 hours and the effect on total FAK or FAK phosphorylation on tyrosine 576 or 861 was assessed by western blotting. Result is representative of three independent experiments. pY418 Src / Src / pY410 CAS / CAS / Py421 Cortactin / Cortactin; PubMed: 20505783 J Cancer Sci Ther Saracatinib inhibits Src activity and downstream Src substrate phosphorylation in HNSCC cell lines. HN31, UMSCC1 and 1483 cells were treated with DMSO vehicle or saracatinib (0.01–1 μM) for 24 h. Cells were lysed and total protein amounts were analyzed by Western blotting with total or phosphorylation site-specific antibodies for Src and the indicated substrates. Blots shown are representative of at least four independent experiments, with band intensities for each substrate quantified relative to the untreated (0 μM) condition for each cell line. p-Akt / p-mTOR / Akt / mTOR / p-S6 / S6 / p-AMPKα / AMPKα; PubMed: 20811583 Genes Cancer PC3 cells were treated with 10 μM PP2 (left panel)/1 μM saracatinib (right panel) for 0.5, 1, 2, 4, 8, and 24 h. Cell lysates were analyzed by immunoblotting with antibodies as indicated. Controls were treated with vehicle alone. β-actin was detected as loading control.	20551056 20505783 20811583
Growth inhibition assay	Cell number; PubMed: 24349321 PLoS One LNCaP 104-S, 104-R1, 104-R2, PC-3, and DU-145 cells were treated with increasing concentrations of Saracatinib for 72 hrs. Relative cell number of LNCaP cells was determined by Hoechst dye 33258-based 96-well proliferation assay. Cell numbers were normalized to control (dimethylsulfoxide) of each cell line. Triple asterisks (***) represent statistically significant difference p <0.001 between the treated group and the control group.	24349321

体内研究

Saracatinib作用于Src3T3异体移植物显示出强的肿瘤生长抑制率，且Saracatinib造成Calu-6, MDA-MB-231, AsPc-1和BT474C移植瘤生长适当延迟。^[1]Saracatinib处理常位DU145鼠，按鼠体重，每千克每天口服处理25mg Saracatinib，结果显示出强的抗癌活性。^[2]

激酶实验： ^[1]	- 合并激酶实验: 使用受体和非受体酪氨酸激酶的重组催化区，通过酶联免疫吸附法测定酪氨酸激酶活性的IC50值。加入的Saracatinib剂量从0.001到10 mM不等。针对丝氨酸/苏氨酸激酶的特定实验是加³²P 的渗透捕捉实验。在加入10 μL 20mM Mg.ATP开始反应前，包含0.5 μL Saracatinib或DMSO（作对照) 或pH 3.0 buffer（作对照）的多支路384孔板加入15 μL酶和肽/蛋白底物温育5分钟。所有酶的最终浓度都接近米氏常数（K_m）。实验在室温下进行30分钟，然后加入5 μL正磷酸终止反应。混合后，孔中的内含物加到P81联合板上，使用正磷酸作为洗涤缓冲液，然后计算IC50值。
细胞实验： ^[2]	- 合并 Cell lines: PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7，和RWPE-1细胞 Concentrations: 62.5 nM-16 mM Incubation Time: 1, 3，和5天 Method: PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7 及RWPE-1细胞按2×10³密度接种在96孔板上，温育过夜。加入浓度不等（62.5 nM-16 mM）的Saracatinib。1,3,5天后分离培养基，每孔加入0.2 mL DMSO，按每分钟200轮持续震荡96孔板15分钟。MTT实验测IC50值。 (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: 移植DU145细胞的CB17鼠 Dosages: 25 mg/kg Administration: 每天口服处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	35 mg/mL warmed (64.57 mM)
	Ethanol	31 mg/mL (57.19 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Saracatinib (AZD0530) SDF

分子量	542.03
化学式	C₂₇H₃₂ClN₅O₅
CAS号	379231-04-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04598919	Recruiting	Drug: Saracatinab\|Drug: Placebo	Idiopathic Pulmonary Fibrosis (IPF)	National Jewish Health\|Yale University\|Icahn School of Medicine at Mount Sinai\|AstraZeneca\|National Center for Advancing Translational Science (NCATS)	November 12 2020	Phase 1\|Phase 2
NCT04307953	Recruiting	Drug: AZD0530 Difumarate\|Drug: Matching placebo	Fibrodysplasia Ossificans Progressiva	VU University Medical Center\|Royal National Orthopaedic Hospital NHS Trust\|Klinikum Garmisch-Patenkirchen\|University of Oxford\|Brigham and Women''s Hospital\|AstraZeneca\|Innovative Medicines Initiative	August 5 2020	Phase 2
NCT02085603	Completed	Drug: Saracatinib\|Drug: Placebo	Cancer	Sheffield Teaching Hospitals NHS Foundation Trust\|AstraZeneca	March 2014	Phase 2
NCT01864655	Completed	Drug: saracatinib\|Drug: Placebo	Alzheimer''s Disease	Stephen M. Strittmatter\|National Institute of Neurological Disorders and Stroke (NINDS)\|Yale University	July 2013	Phase 1
NCT01000896	Withdrawn	Drug: AZD0530\|Drug: Carboplatin\|Drug: paclitaxel	Cancer\|Non Small Cell Lung Cancer\|Epithelial Ovarian Cancer	AstraZeneca	January 2010	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the half-life of Saracatinib?
回答：
Based on the following paper, the half-life of Saracatinib in vivo is around 40hours and it reaches its peak lever around 2-4 hours after dosing: http://clincancerres.aacrjournals.org/content/16/19/4876.long

Src Signaling Pathway Map

Src Inhibitors with Unique Features

活性最高的Src抑制剂

Dasatinib : Src, IC50=0.8 nM.
FDA批准的Src抑制剂

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
最新的Src抑制剂

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
经典的Src抑制剂

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

研究领域

产品类型

定制您的化合物库

Saracatinib (AZD0530)

客户使用Selleck生产的Saracatinib (AZD0530)发表文献225篇：

产品安全说明书

Src抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Saracatinib (AZD0530) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

常见问题及建议解决方法

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品